The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise
Roche will get another reminder this week about just how important its late-stage pipeline is these days.
Thursday, the FDA’s committee of outside cancer experts …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
